BioNTech, DualityBio Breast Cancer Drug Shows Modest Progression-Free Survival Gain in Phase 3 Trial
Bitget2026/10/26 09:01- BioNTech and DualityBio announced topline results from the Phase 3 DYNASTY-Breast02 breast cancer trial on October 26, 2026.
- Trastuzumab pamirtecan modestly delayed disease progression versus chemotherapy in chemotherapy-naive patients with HR+/HER2-low metastatic breast cancer whose disease progressed on endocrine therapy.
- Overall survival data were not mature at the interim analysis.
- Interstitial lung disease occurred more frequently than in prior trials, mostly as mild or moderate cases; some cases were severe or fatal.
- The partners see limited potential patient benefit in the current treatment landscape and will review the data to determine next steps.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.


Bitcoin rebounds sharply from oversold levels, briefly surpassing $57,000
